239 related articles for article (PubMed ID: 15968284)
21. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.
Rasmussen T; Hansson L; Osterborg A; Johnsen HE; Mellstedt H
Blood; 2003 Jun; 101(11):4607-10. PubMed ID: 12576327
[TBL] [Abstract][Full Text] [Related]
22. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
[TBL] [Abstract][Full Text] [Related]
23. Active immunotherapy of multiple myeloma.
Houet L; Veelken H
Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966
[TBL] [Abstract][Full Text] [Related]
24. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
25. Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation.
Libura J; Hoffmann T; Passweg J; Gregor M; Favre G; Tichelli A; Gratwohl A
Bone Marrow Transplant; 1999 Oct; 24(8):925-7. PubMed ID: 10516707
[TBL] [Abstract][Full Text] [Related]
26. A randomized study on donor immunization with tetanus-diphtheria, Haemophilus influenzae type b and inactivated poliovirus vaccines to improve the recipient responses to the same vaccines after allogeneic bone marrow transplantation.
Parkkali T; Käyhty H; Hovi T; Olander RM; Roivainen M; Volin L; Ruutu T; Lahdenkari M; Ruutu P
Bone Marrow Transplant; 2007 Feb; 39(3):179-88. PubMed ID: 17211432
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease.
Natzke AM; Shaw JL; McKeller MR; Emo KL; Mullen CA
Biol Blood Marrow Transplant; 2007 Jan; 13(1):34-45. PubMed ID: 17222751
[TBL] [Abstract][Full Text] [Related]
28. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M;
Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
30. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
31. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
[TBL] [Abstract][Full Text] [Related]
33. Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors.
Hows JM; Passweg JR; Tichelli A; Locasciulli A; Szydlo R; Bacigalupo A; Jacobson N; Ljungman P; Cornish J; Nunn A; Bradley B; Socié G; ;
Bone Marrow Transplant; 2006 Dec; 38(12):799-805. PubMed ID: 17075568
[TBL] [Abstract][Full Text] [Related]
34. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
Reichardt VL; Okada CY; Stockerl-Goldstein KE; Bogen B; Levy R
Biol Blood Marrow Transplant; 1997 Aug; 3(3):157-63. PubMed ID: 9310193
[TBL] [Abstract][Full Text] [Related]
35. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling.
Lisini D; Zecca M; Giorgiani G; Montagna D; Cristantielli R; Labirio M; Grignani P; Previderè C; Di Cesare-Merlone A; Amendola G; Bergami E; Mastronuzzi A; Maccario R; Locatelli F
Haematologica; 2008 Dec; 93(12):1859-67. PubMed ID: 18945748
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
38. [The molecular characteristics of T-cell immune reconstitution in leukemia patients after allogeneic hematopoietic stem cell transplantation].
Fu YW; Wu DP; Sun AN; Feng YF; Chang WR; Zhu ZL; Zhu P
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):312-7. PubMed ID: 17877159
[TBL] [Abstract][Full Text] [Related]
39. [Distribution of immunoglobulin like receptor gene in Han population in China and the impact thereof on the HLA-identical sibling hematopoietic stem cell transplantation].
Dou LP; DA WM; Zhao DD; Wang C; Lu XC; Kang HY; Yan P; Wang FF; Zhu HY; Li HH; Gao CJ; Yu L
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3111-4. PubMed ID: 18269867
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in multiple myeloma: current strategies and future prospects.
Yi Q
Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
